The real cons of Wegovy: side effects, limitations and what patients are rarely told upfront

The myth that 'side effects are mild and temporary' — and the fuller picture

The most common misconception about Wegovy is that GI side effects are a brief, minor nuisance. For many people they are exactly that. Nausea tends to be worst in the first week or two after starting or increasing a dose, then settles as the body adjusts. But for a meaningful minority, symptoms are persistent enough to affect daily life, and some people discontinue treatment because of them.

The full list from clinical trial data includes nausea, vomiting, diarrhoea, constipation, burping, acid reflux and fatigue. Headaches and dizziness also appear. The NHS semaglutide medicines page lists these in plain terms and is worth reading before starting. Less commonly, pancreatitis has been reported: in January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines specifically flagging acute pancreatitis as an infrequent but potentially serious risk, with severe and persistent stomach pain that may spread to the back as the warning sign requiring urgent medical attention.

There are also gallbladder considerations. Rapid weight loss of any kind can increase the risk of gallstones, and semaglutide is no exception. This does not mean it will happen, but it is a real factor in the risk-benefit calculation a prescriber makes on your behalf. If you want a fuller comparison of the drawbacks alongside the benefits, the pros and cons of Wegovy page sets both sides out clearly.

The bottom line: the side-effect profile is real, not imagined, and worth taking seriously, even if most people manage it well with gradual dose escalation and dietary adjustments.

The ongoing commitment Wegovy actually requires

A second misconception is that Wegovy works passively. It does not. Appetite suppression from semaglutide creates a window; what happens in that window depends on what someone eats, how they move, and whether they have clinical support to navigate the adjustment. The licence specifically requires it to be used alongside a reduced-calorie diet and increased physical activity.

Beyond lifestyle, there is the prescribing commitment. Wegovy is a prescription-only medicine. Every supply requires clinical review, and legitimate services carry out that review before every repeat order. That is not bureaucracy; it is patient safety. A prescriber checks that the medicine is still appropriate, that weight loss is progressing, and that no new contraindications have appeared.

You can explore how the dose stages work, and how they are managed clinically, on the Wegovy dose levels page. The titration schedule, from 0.25mg upward to the 2.4mg maintenance dose (or the newer 7.2mg option), is longer than many people expect, taking several months to reach full therapeutic dose.

There is also the question of duration. NICE's guidance on semaglutide for weight management under TA875 permits NHS use for a maximum of two years within specialist services. Private treatment has no such time cap by regulation, but the weight-regain evidence after stopping is significant. That is not a reason to avoid treatment; it is a reason to plan for it honestly with a prescriber.

Cost and access: the con nobody hides but few quantify

Private Wegovy treatment in the UK is not cheap. Since Eli Lilly's list price increase for Mounjaro in September 2025, the broader market has shifted, and typical private prices for Wegovy now run roughly in the range of £150 to over £300 a month depending on dose and provider, as widely reported. That cost, repeated monthly, accumulates quickly.

For those hoping to access Wegovy through the NHS, the wait can be long. NICE recommended semaglutide under TA875, but only within specialist weight management services with multidisciplinary support. GP referral timelines and service capacity vary considerably by area. If you are assessing the financial picture, the Wegovy cost page breaks down what private treatment typically includes and what to watch for in headline prices that exclude clinical fees or aftercare.

One honest thing to acknowledge here: if you are reading this, you may already feel frustrated. Frustrated with the NHS waiting times, with prices that feel steep for a medicine that is not optional for some people, with information online that ranges from breathless enthusiasm to scare-mongering. That frustration is reasonable. The goal of this page is simply to give you the factual picture so you can make a decision you feel confident in.

Who Wegovy is not suitable for, and what that means in practice

Wegovy is not suitable for everyone, and this matters more than the side-effect list for some readers. It is not licensed for use in pregnancy, breastfeeding, or in people actively trying to conceive; clinical guidance recommends stopping treatment and waiting an appropriate period before attempting pregnancy. Under-18s are excluded. People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use it, nor should those with a history of pancreatitis without a clear resolved cause.

Oral contraceptive absorption may not be significantly affected by semaglutide in the way it is with tirzepatide, but NHS guidance still advises discussing contraception with your prescriber before starting any GLP-1 medicine. The semaglutide page covers the medication in more detail, including contraindications and how eligibility is assessed. You can also read about the stages of Wegovy treatment to understand what clinical monitoring looks like across the treatment journey.

BMI thresholds also apply. The licence covers adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. BMI alone does not guarantee clinical approval. A prescriber weighs the full picture, including your other medicines and medical history.

If you are weighing Wegovy against other options, the weight-loss treatments overview page sets out the licensed options available in the UK and how they differ. For a broader look at Wegovy specifically, the Wegovy treatment page covers efficacy, access and what to expect from treatment. And if you have questions about whether you would be clinically suitable, the best next step is a consultation where a real prescriber reviews your individual circumstances.